Ciloa, a member of the ImmuneNOVA European consortium, has been earmarked for funding.
The ImmuneNOVA project has been labelled by EUROSTARS, an action funded by Eureka member countries and the European Union Horizon 2020 Framework Program. The project aims to develop a first in class inhibitor of a challenging membrane protein involved in the control of an immune checkpoint.
